Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. (Q25256974)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Jean-Paul Ortonne

1

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Neil Shear

2

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Stephen Shumack

3

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Eric Henninger

4

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

CLEAR Multinational Study Group

5

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

language of work or name

0 references

publication date

16 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

BMC Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1

0 references

13

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

7 April 2017

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

7 April 2017

A critical review of Quality-of-Life Scales for Psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

Ciclosporin in psoriasis clinical practice: an international consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

Quality of life in patients with psoriasis: a systematic literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

The immunologic basis for the treatment of psoriasis with new biologic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

Trivial or terrible? The psychosocial impact of psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

Oral retinoids--efficacy and toxicity in psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 September 2017

Psoriasis causes as much disability as other major medical diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

31 May 2018

Methotrexate in psoriasis: consensus conference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

31 May 2018

Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients With Skin Diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

31 May 2018

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

31 May 2018

Assessment of depression in subjects with psoriasis vulgaris and lichen planus.

1 reference

https://api.crossref.org/works/10.1186%2F1471-5945-5-13

21 January 2018

The burden of psoriasis is not determined by disease severity only.

1 reference

https://api.crossref.org/works/10.1186%2F1471-5945-5-13

21 January 2018

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

1 reference

https://api.crossref.org/works/10.1186%2F1471-5945-5-13

21 January 2018

Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin

1 reference

https://api.crossref.org/works/10.1186%2F1471-5945-5-13

21 January 2018

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-5945-5-13

21 January 2018

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-5945-5-13

21 January 2018

Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-5945-5-13

21 January 2018

Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 November 2018

The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 November 2018

Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1343580

28 November 2018

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16359548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16359548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suicidal ideation in psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16359548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16359548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16359548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16359548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-5945-5-13

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q25256974&oldid=2177063833"